The chimeric transcript RUNX1-GLRX5: A biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer

Rie Ishikawa; Yosuke Amano; Masanori Kawakami; Mitsuhiro Sunohara; Kousuke Watanabe; Hidenori Kage; Nobuya Ohishi; Yutaka Yatomi; Jun Nakajima; Masashi Fukayama; Takahide Nagase; Daiya Takai

doi:10.1093/jjco/hyv187

The chimeric transcript RUNX1-GLRX5: A biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer

Rie Ishikawa
, Yosuke Amano
, Masanori Kawakami
, Mitsuhiro Sunohara
, Kousuke Watanabe
, Hidenori Kage
, Nobuya Ohishi
, Yutaka Yatomi
, Jun Nakajima
, Masashi Fukayama
, Takahide Nagase
, Daiya Takai

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1-GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimerawas detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3%). Although therewas no significant difference in the overall survival rate between RUNX1-GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1-GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1- GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.

Original language	English (US)
Article number	hyv187
Pages (from-to)	185-189
Number of pages	5
Journal	Japanese journal of clinical oncology
Volume	46
Issue number	2
DOIs	https://doi.org/10.1093/jjco/hyv187
State	Published - Feb 1 2016

Keywords

Biological markers
GLRX5
Gene fusion
Non-small-cell lung cancer
RUNX1

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1093/jjco/hyv187

Cite this

Ishikawa, R., Amano, Y., Kawakami, M., Sunohara, M., Watanabe, K., Kage, H., Ohishi, N., Yatomi, Y., Nakajima, J., Fukayama, M., Nagase, T., & Takai, D. (2016). The chimeric transcript RUNX1-GLRX5: A biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer. Japanese journal of clinical oncology, 46(2), 185-189. Article hyv187. https://doi.org/10.1093/jjco/hyv187

Ishikawa, R, Amano, Y, Kawakami, M, Sunohara, M, Watanabe, K, Kage, H, Ohishi, N, Yatomi, Y, Nakajima, J, Fukayama, M, Nagase, T & Takai, D 2016, 'The chimeric transcript RUNX1-GLRX5: A biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer', Japanese journal of clinical oncology, vol. 46, no. 2, hyv187, pp. 185-189. https://doi.org/10.1093/jjco/hyv187

@article{a06a43fe4d8547028da76c26ddc35cbf,

title = "The chimeric transcript RUNX1-GLRX5: A biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer",

abstract = "Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1-GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimerawas detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3\%). Although therewas no significant difference in the overall survival rate between RUNX1-GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1-GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1- GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.",

keywords = "Biological markers, GLRX5, Gene fusion, Non-small-cell lung cancer, RUNX1",

author = "Rie Ishikawa and Yosuke Amano and Masanori Kawakami and Mitsuhiro Sunohara and Kousuke Watanabe and Hidenori Kage and Nobuya Ohishi and Yutaka Yatomi and Jun Nakajima and Masashi Fukayama and Takahide Nagase and Daiya Takai",

note = "Publisher Copyright: {\textcopyright} The Author 2016.",

year = "2016",

month = feb,

day = "1",

doi = "10.1093/jjco/hyv187",

language = "English (US)",

volume = "46",

pages = "185--189",

journal = "Japanese journal of clinical oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - The chimeric transcript RUNX1-GLRX5

T2 - A biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer

AU - Ishikawa, Rie

AU - Amano, Yosuke

AU - Kawakami, Masanori

AU - Sunohara, Mitsuhiro

AU - Watanabe, Kousuke

AU - Kage, Hidenori

AU - Ohishi, Nobuya

AU - Yatomi, Yutaka

AU - Nakajima, Jun

AU - Fukayama, Masashi

AU - Nagase, Takahide

AU - Takai, Daiya

N1 - Publisher Copyright: © The Author 2016.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1-GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimerawas detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3%). Although therewas no significant difference in the overall survival rate between RUNX1-GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1-GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1- GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.

AB - Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1-GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimerawas detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3%). Although therewas no significant difference in the overall survival rate between RUNX1-GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1-GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1- GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.

KW - Biological markers

KW - GLRX5

KW - Gene fusion

KW - Non-small-cell lung cancer

KW - RUNX1

UR - https://www.scopus.com/pages/publications/84961661976

UR - https://www.scopus.com/pages/publications/84961661976#tab=citedBy

U2 - 10.1093/jjco/hyv187

DO - 10.1093/jjco/hyv187

M3 - Article

C2 - 26685324

AN - SCOPUS:84961661976

SN - 0368-2811

VL - 46

SP - 185

EP - 189

JO - Japanese journal of clinical oncology

JF - Japanese journal of clinical oncology

IS - 2

M1 - hyv187

ER -

The chimeric transcript RUNX1-GLRX5: A biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this